Ipsen Confident in U.S. Neurology Push Despite Dysport Delay
Neither FDA’s REMS request nor the prospect of competing with Allergan’s Botox appears to be spoiling Ipsen’s plans to stake a U.S. neurology stronghold.
Neither FDA’s REMS request nor the prospect of competing with Allergan’s Botox appears to be spoiling Ipsen’s plans to stake a U.S. neurology stronghold.